Opinion & analysis

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

As the number of cancer survivors increases, they are reshaping cancer research and clinical practice. Find out how–and discover the impact it will have on the allocation of research dollars. Learn how the looming physician shortage has implications for the emergence and increasing use of complex immunotherapy drugs.

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

NASH: Flying The Plane While Building It

J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says

Thinking about using CMMI? Here are tips from the experts

It’s Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

The Blockbusters No One Talks About

Pharma’s New R&D Models: Federating Innovation

Bayer’s US Playbook: The Smart Way To Top-Line Growth

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

New Reasons Not To Use EU MDR’s Four-Year Extension, But Comply Earlier Or Retire Products Instead

Paying For Gene Therapy: Will Pharma Be First In Line?

Cosmetic Preservatives Crisis Creeping Into CIR Program

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

Novartis’ New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands

Regulatory headaches: Brexit’s not the only thing you need to worry about

ASCO 2018: Optimism As Industry Resets And Looks To What Is Next

Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Sunshine rules in the EU: Implications of a piecemeal approach

FDA investigator insights: Device makers forget about the humans who use their products

Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens

Infographic – 2018 Pharma Pipeline Snapshot

UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

‘Something’s Going To Happen’: Former FDAer John Bailey On Cosmetics Reform Legislation

Immuno-Oncology: What To Watch At ASCO 2018

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

Takeda/Shire Merger: Five Things To Worry About

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

Pfizer’s Reference Point on Trial Innovation : Ask the Patient

US FDA Commissioner: Agency Will Propose New Rule That Blends Quality System Regulation, ISO 13485

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?

GSK’s Head Of Artificial Intelligence Unveils R&D Goals

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View